ViroPharma to Present at Three November Healthcare Conferences

EXTON, Pa., Oct. 29 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq:
VPHM) today announced that the company will be presenting at several upcoming
healthcare investment conferences.

Vincent Milano, president and chief executive officer of ViroPharma, will
present at the Oppenheimer 20th Annual Healthcare Conference at 4:30 P.M. EST
on Tuesday, November 3, 2009. The conference is being held at the
Waldorf=Astoria in New York City.

Charles Rowland, vice president and chief financial officer of ViroPharma,
will present at the Credit Suisse 2009 Healthcare Conference at 12:00 P.M. MST
on Wednesday, November 11, 2009. The conference is being held at the Arizona
Biltmore Hotel in Phoenix, AZ.

William Roberts, vice president, corporate communications will present at the
Lazard Capital Markets 6th Annual Healthcare Conference at 2:45 P.M. EST on
Wednesday, November 18, 2009. The conference is being held at the St. Regis
Hotel in New York City.

ViroPharma's presentations will be webcast live for investors through
www.viropharma.com and available for a period of 14 days following the
conferences.

About ViroPharma Incorporated

ViroPharma Incorporated is a biopharmaceutical company dedicated to the
development and commercialization of products that address serious diseases
treated by physician specialists and in hospital settings. ViroPharma
commercializes Vancocin®, approved for oral administration for treatment of
antibiotic-associated pseudomembranous colitis caused by Clostridium difficile
and enterocolitis caused by Staphylococcus aureus, including
methicillin-resistant strains. ViroPharma commercializes Cinryze(TM) (C1
esterase inhibitor (human)) for routine prophylaxis against angioedema attacks
in adolescent and adult patients with hereditary angioedema (HAE), also known
as C1 inhibitor deficiency (for prescribing information on ViroPharma's
commercial products, please download the package inserts at
http://www.viropharma.com/Products.aspx). ViroPharma currently focuses its
drug development activities in diseases including cytomegalovirus (CMV), HAE
and C. difficile.

ViroPharma routinely posts information, including press releases, which may be
important to investors in the investor relations and media sections of our
company's web site, www.viropharma.com. The company encourages investors to
consult these sections for more information on ViroPharma and our business.

SOURCE ViroPharma Incorporated

Robert A. Doody Jr., Assistant Director, Investor Relations, ViroPharma
Incorporated, +1-610-321-6290